Rubio GAF, Lozano NJJ, Vargas AG, Rodríguez LL, Garrido PH

Language: Spanish
References: 22
Page: 291-295
PDF size: 55.28 Kb.

ABSTRACT

The association of hypertension and diabetes increases the risk of cardiac and microvascular complications in patients. Moreover, high blood pressure accelerates the progression of diabetic nephropathy. Hypertension control in diabetic patients must be the top priority for prevention of cardiac and renal complications. It is now recommended to start drug therapy with lower values of blood pressure than those accepted for non-diabetic patients. However, recommendations are based on studies with great number of non-diabetic hypertensive patients. Diabetic hypertensive patients have been included in recent trials. In this paper we review the therapeutic strategies in the management of hypertensive diabetic patients based on such clinical trials.

REFERENCES

1. Ruilope LM, De la Sierra A, Moreno E, et al. Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial: the EDICTA study. J Hypertens 1999;17:1917-23.

2. Caballero FJ, Rubio AF, Vargas G, et al. Aterosclerosis carotídea e ilíaca en pacientes con diabetes mellitus no dependiente de insulina. Med Int Mex 1997;13:259-62.

3. Molitch ME. Management of early diabetic nephropathy. Am J Med 1997;102:392-8.

4. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151-83.

5. Bakris GL. Lower blood pressure goals for patients with diabetes: The National Kidney Foundation Consensus Report. J Clin Hypertens 2000;2:369-71.

6. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.

7. Moreno MV, Rubio AF, Rodríguez L, Lozano JJ. Causas de insuficiencia renal crónica. Hospital General de Ticomán 1988-1944. Med Int Mex 1996;12:159-62.

8. Heart Outcome Prevention Evaluation Study Investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICRO-HOPE substudy. Lancet 2000;355:253-9.

9. Hansson L, Zanchetti A, Carruthers G, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. HOT Study Group. Lancet 1998;351:1755-62.

10. Staessen JA, Fagal R, Lutgarde T, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) trial Investigators. Lancet 1997;350:757-64.

11. Palatini P. Management of hypertension in the diabetic patient. In: Zanchetti A, Hansson L, Rodicio JL, editors. Hypertension. Parma: McGraw Hill, 2001;pp:201-7.

12. Grossman E, Messerli FH, Goldbourt U, High blood pressure and diabetes mellitus. Are all antihipertensive drugs created equal? Arch Intern Med 2000;160:2447-52.

13. Bakris GL. Management of hypertensive patients with diabetic nephropaty. In: Izzo JL, Black HR, editors. Hypertension premier. Dallas: American Heart Association, 1999;pp:421-3.

14. Kaplan NM. Management of hypertension in patients with type 2 diabetes mellitus: guidelines base on current evidence. Ann Intern Med 2001;135:1079-83.

15. Niskanen L, Hedner T, Hansson L, et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first line therapy with an ACE inhibitor compared with a diuretic/b blocker-based treatment regimen. CAPPP Study Group. Diabetes Care 2001;24:2091-6.

16. Brenner B, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.

17. Lewis E, Hunsicker L, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.

18. Tatti P, Pahor M, Byington R, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.

19. Bakris G, Weir MR, DeQuatro V, McMahon FG. Effects of an ACE inhibitor /calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283-9.

20. Rubio AF, Treviño CJ, Vargas G, et al. Trandolapril-verapamil reduces proteinuria in diabetic hypertensive patients insufficiently pretreated with an ACE inhibitor and in spite of a poor glycemic control. Am J Hypertens 2000;13:54A.

21. De Marie BK, Bakris GI. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med 1990;113:987-8.

22. Trejo N, Rubio AF, Rodríguez L, et al. Efectos del perindopril vs amlodipino en la presión del pulso en el manejo de sostén de pacientes con hipertensión descontrolada. Rev Mex Aterosc Prev Card 2001;4:33-36.